The $1.5B acquisition of BioLife Solutions accelerates leadership in cell therapy, adds a highly complementary portfolio, and is immediately accretive to growth and margins. Integration is expected to be straightforward, with significant cost and revenue synergies, especially in Asia-Pacific.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.